RYTM - Rhythm Pharmaceuticals rallies as upgraded to neutral at BofA on strong BBS launch

• BofA analyst Tazeen Ahmad upgraded Rhythm Pharmaceuticals ( RYTM ) to Neutral from Underperform with a price target of $20, up from $8.
• The company is seeing a strong early BBS launch performance, Ahmad tells investors following the company's Q2 report.
• However, Ahmad awaits further color on the sustainability of the early metrics to get more constructive.
• Rhythm Pharmaceuticals SA Quant Rating stands with Hold whereas, Wall St. Analysts Rating says to Buy (4 Very Bullish, 1 Bullish, 1 Bearish).
• Since the start of 2022, Rhythm Pharmaceuticals shares were up around 86% , and over a period of one year, shares were up around 41% .
• Shares are currently +6.51% to $19.80 today.

For further details see: